Thermo Fisher Scientific Inc. $TMO Position Raised by Spinnaker Trust

Spinnaker Trust raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 10,812 shares of the medical research company’s stock after buying an additional 212 shares during the quarter. Spinnaker Trust’s holdings in Thermo Fisher Scientific were worth $4,384,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in TMO. CBIZ Investment Advisory Services LLC increased its holdings in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares during the period. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter valued at $30,000. Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter valued at $31,000. DiNuzzo Private Wealth Inc. increased its holdings in shares of Thermo Fisher Scientific by 406.7% during the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 61 shares during the period. Finally, HighMark Wealth Management LLC increased its holdings in shares of Thermo Fisher Scientific by 140.6% during the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 45 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 17,104 shares of the firm’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 54,420 shares of company stock valued at $28,134,684. 0.33% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Argus raised their price target on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a report on Wednesday. Scotiabank raised Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. TD Cowen lifted their target price on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Nineteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $601.65.

Thermo Fisher Scientific Trading Up 0.1%

Shares of TMO opened at $558.28 on Thursday. The business’s 50-day moving average price is $508.04 and its 200 day moving average price is $456.10. The stock has a market capitalization of $210.81 billion, a P/E ratio of 32.25, a P/E/G ratio of 3.26 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the business posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.